FDA Clearance Tracker · P990009-S037
FLOSEAL HEMOSTATIC MATRIX
Last checked: Nov 20, 2026Latest source record: May 27, 2014 (this decision)Source: openFDAMethods & limitations
Decided
May 27, 2014
Approved
Time to decision
355 days
Received Jun 6, 2013. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990009-S037
- Device name
- FLOSEAL HEMOSTATIC MATRIX
- Applicant
- Baxter Healthcare Corp
- Applicant location
- Round Lake, IL
- Received
- Jun 6, 2013
- Decided
- May 27, 2014
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P990009
Device type
- Device class
- Class III
- Regulation
- 21 CFR 878.4490
- Specialty
- General & Plastic SurgeryWound Care
FDA's approval statement
As written in FDA's record.
APPROVAL FOR REVISED LABELING TO INCLUDE A SUMMARY OF THE NASSO ET AL. CLINICAL TRIAL, UPDATE THE DEVICE DESCRIPTION, AND EXTEND THE THROMBIN RECONSTITUTION PERIOD.
Source documents
Other decisions for Baxter Healthcare Corp
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Helion Viewer Suite510(k)
K254265 · Decided May 27, 2026 · 148 days after receipt
Device type: System, Image Processing, Radiological (LLZ) · Radiology & Imaging
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.